Introduction to a novel therapeutic strategy to inhibit exosomes that contribute to cancer progression

1. A Novel Therapeutic Strategy
to Address Cancer
September 2011

2. Cancer is the leading cause of death
worldwide and accounted for 7.6 million
deaths in 2008 alone

3. There were 12.7 million new cases of
Cancer in 2008

4. Cancer deaths in the United States
are expected to exceed 570,000 in 2011

6. In 2011, new cases of Cancer are
expected to exceed 1,500,000 in the U.S.

8. Innovative strategies are needed
to address Cancer progression
mechanisms that are beyond the
reach of current drug therapies

9. A therapeutic strategy that could inhibit the
proliferation of immunosuppressive exosomes
released by solid tumors, lymphomas and
leukemias would fill a significant unmet
medical need in cancer care

10. What are Exosomes?
• Cancer cells, both in vivo
and in vitro, have been
demonstrated to release
membranous structures,
defined as exosomes

11. Researchers have recently unveiled several
roles that exosomes play in accelerating
cancer progression

12. The resulting research publications
are reporting that................

13. Exosomes cause apoptosis or programmed
cell death of immune cells

14. Exosomes disrupt signaling of
anti-cancer T cells

15. Exosomes contribute to tumor angiogenesis

16. Exosomes enhance the spread of tumor metastasis

17. The quantity of exosomes in circulation is in
direct correlation with cancer progression

18. What if exosomes could be
eliminated from circulation?

19. The Aethlon Hemopurifier®
The first therapeutic candidate to eliminate
cancer exosomes from circulation

20. The Aethlon Hemopurifier®
• Provides a therapeutic filtration
mechanism to remove cancer
exosomes from the circulatory
system
• Allows selective exosome capture
via unique high-mannose
signatures resident on exosome
surfaces

21. Providing access to the entire
circulatory system
• Exosomes can be accessed
from entire circulatory system,
which can pass through the
Hemopurifier® in as little as
15 minutes

22. Hemopurifier® therapy has the advantage of being
delivered through the global infrastructure of dialysis
machines that are already located in hospitals in clinics

23. Our goal is to improve patient responsiveness
to traditional chemotherapies and emerging
classes of immune based therapies

24. To improve patient responsiveness without
additional drug toxicity or interaction risks

25. In vitro binding of exosomes underlying the
following cancers has been demonstrated
• Breast
• Ovarian
• Colorectal
• Lymphoma
• Melanoma

26. Human Hemopurifier® treatment
experience already exists

27. The Hemopurifier® has previously demonstrated
the ability to reduce viral load in HIV and
hepatitis C (HCV) infected individuals without the
administration of antiviral drugs

28. A clinical study to evaluate the ability of the
Hemopurifier® to improve HCV drug therapy
benefit is currently being conducted

29. The clinical application of the
Hemopurifier® in Cancer?

30. We are currently collaborating with
candidate investigators to develop a clinical
protocol to demonstrate the ability of our
Hemopurifier® to eliminate circulating
cancer exosomes

31. We invite you to follow our efforts
to improve cancer care
AethlonMedical.com

32. Our mission is to create innovative devices that
address unmet medical needs in cancer, infectious
disease, and other life-threatening conditions
Thank You

33. Contact
Jim Joyce
Chairman, CEO
8910 University Center Lane
San Diego, California 92122
jj@aethlonmedical.com

34.
This presentation contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, and Aethlon Medical intends that such forward-looking statements be
subject to the safe harbor created thereby. These statements are based on management’s current
expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could
cause actual results to differ materially from those described. All statements, other than statements of
historical fact, are statements that could be deemed forward-looking statements, including the company’s
ability to successfully obtain FDA and other regulatory approvals for the sale of its products, the
capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat
disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the
impact that potential ability may have on disease conditions, and the company’s ability to raise capital
when needed.
Some information in this presentation, or on which this presentation is based, has been obtained from
sources that Aethlon Medical, Inc., believes to be reliable and accurate. However, it has not been
independently verified and no representation or warranty, express or implied, is made as to the accuracy
or completeness of any information obtained from third parties.
Such risks and uncertainties, including those discussed above, are more fully described in the Securities
and Exchange Commission (SEC) reports filed by Aethlon Medical, Inc., including its most recent annual
report on Form 10-K. This presentation speaks only as of its date, and the company disclaims any duty
to update the information herein. Further information is available by contacting the company or at the
company’s website at www.aethlonmedical.com.